AAL

Analyst: This Penny Stock Could Triple

The analyst is optimistic about Chiasma's Mycapssa prospects

Mar 7, 2019 at 12:49 PM
facebook X logo linkedin


The shares of Chiasma Inc (NASDAQ:CHMA) are modestly higher today, after the pharma stock scored a very bullish brokerage note. Specifically, Cantor Fitzgerald launched coverage of CHMA with an "outperform" rating and $18 price target -- more than three times the equity's current price, and in territory not charted in three years. The analyst waxed optimistic on the prospects for Chiasma's Mycapssa, and said the "current entry point [looks] attractive for investors."

At last check, CHMA stock was up 0.9% at $5.89, after soaring to a fresh two-year high of $6.14 out of the gate. The stock is now set for its highest close since a massive bear gap in April 2016 -- sparked by a Food and Drug Administration (FDA) rejection for the company's oral treatment for acromegaly --  and has already soared nearly 400% since bottoming at $1.20 in mid-August.

 CHMA stock chart march 7

Chiasma stock is no stranger to bullish analyst attention, though. All four brokerage firms following CHMA deem it worthy of a "buy" or better, and the consensus 12-month price target of $14.25 represents expected upside of more than 140% to the equity's current price.

Short interest, meanwhile, is near 52-week lows. Less than 0.2% of CHMA's stock is dedicated to short interest, representing not even a day of pent-up buying demand, at the security's average pace of trading.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.